- Country: Panama
- Summary: Clindamycin Phosphate, 150 Mg/Ml, Solution; Dobutamine 250 Mg, Solution; Norepinephrine Bitartrate, Equivalent to Norepinephrine 1 Mg/Ml, Solution; Mannitol 20%, Solution for Intravenous Infusion
- PAT Ref No: 96708371
- Deadline: 22 Feb 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: PAB 26258.84
- Notice Type: Tender
- Document Ref. No.: 2024-0-12-224-09-CM-014719
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Clindamycin Phosphate, 150 Mg/ml, Solution; Dobutamine 250 Mg, Solution; Norepinephrine Bitartrate, Equivalent to Norepinephrine 1 Mg/ml, Solution; Mannitol 20%, Solution For Intravenous Infusion
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINClindamycin Phosphate, 150 Mg/Ml, Solution; Dobutamine 250 Mg, Solution; Norepinephrine Bitartrate, Equivalent to Norepinephrine 1 Mg/Ml, Solution; Mannitol 20%, Solution for Intravenous Infusion - Panama Tender
The MINISTRY OF HEALTH, a Government sector organization in Panama, has announced a new tender for Clindamycin Phosphate, 150 Mg/Ml, Solution; Dobutamine 250 Mg, Solution; Norepinephrine Bitartrate, Equivalent to Norepinephrine 1 Mg/Ml, Solution; Mannitol 20%, Solution for Intravenous Infusion. This tender is published on PanamaTenders under PAT Ref No: 96708371 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-02-22.
The estimated tender value is PAB 26258.84, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
